Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Cancer Discovery|2022Cited by 139
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J. Jaehnig, Meenakshi Anurag, Haoquan Zhao et al.|Cell Reports Medicine|2025Cited by 3
Data from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0